07:00 , Oct 9, 2014 |  BC Innovations  |  Cover Story

Invigorating IVIG

  Although IVIG has been a mainstay in autoimmune disease therapy for decades, there is still high variability in both safety and potency among different batches because the antibodies are sourced from pooled human blood....
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Emergent BioSolutions, U.S. Centers for Disease Control and Prevention infectious news

Emergent said the CDC exercised options under a 2012 award valued at $18.9 million over three years for Emergent to supply Vaccinia Immune Globulin Intravenous (VIGIV) for the U.S. strategic national stockpile. The purified antibody...
07:00 , May 2, 2011 |  BioCentury  |  Finance

Familiarity breeds content

European life sciences firm LSP raised €36 million ($52.5 million) last week in an IPO for its first in-house fund to invest in public companies. The firm is capitalizing on investors' familiarity with its venture...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Clinical News

Gamunex-C regulatory update

FDA approved subcutaneous and IV formulations of Gamunex-C immune globulin to treat primary immunodeficiency. The agency also approved IV Gamunex-C to treat chronic inflammatory demyelinating polyneuropathy (CIDP) and idiopathic thrombocytopenic purpura (ITP). Talecris Biotherapeutics Inc....
07:00 , Aug 2, 2010 |  BioCentury  |  Finance

mAb money tree

Not for the first time, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) translated its VelocImmune antibody discovery technology into a deal that is heavy on guaranteed money. Last week, Astellas Pharma Inc. (Toyko:4053) paid $165 million in cash...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Company News

Grifols, Talecris deal

Grifols plans to acquire fellow plasma protein company Talecris in a cash and stock deal that the companies said values Talecris at $26.16 per share, or about $3.4 billion. The price is a 64% premium...
07:00 , Jun 14, 2010 |  BioCentury  |  Finance

Talecris takeout, again

Talecris takeout, again Investors in the October 2009 IPO by Talecris Biotherapeutics Inc. (NASDAQ:TLCR) will get their initial investment back in cash, plus a bit tacked on in shares, under a takeout bid from fellow...
00:53 , Jun 8, 2010 |  BC Extra  |  Top Story

Grifols to acquire Talecris

Grifols S.A. (Madrid:GRF) plans to acquire fellow plasma protein company Talecris Biotherapeutics Inc. (NASDAQ:TLCR) in a cash and stock deal that the companies said values Talecris at $26.16 per share, or about $3.4 billion. The...
07:00 , May 3, 2010 |  BioCentury  |  Finance

Ontario on oncology

The conventional gripe in Canada is that there is a dearth of early stage investment funds. But Ontario has an early stage vehicle that any U.S. state would be happy to have. The Ontario Institute...
00:38 , Oct 2, 2009 |  BC Extra  |  Top Story

Talecris prices IPO

Talecris Biotherapeutics Inc. (NASDAQ:TLCR) raised $550 million through the sale of 28.9 million shares at $19 in an IPO underwritten by Morgan Stanley; Goldman Sachs; Citigroup; JPMorgan; Wells Fargo; Barclays Capital; and UBS. The price...